{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:36:40Z","timestamp":1759160200107,"version":"3.37.3"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["L30 CA162355"],"award-info":[{"award-number":["L30 CA162355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Relapsed aggressive lymphomas are often treated with platinum\u2010based chemotherapy (<jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>) followed by an autologous stem cell transplant (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>). Response rates to <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content> in patients with relapsed aggressive lymphomas are <jats:italic>c<\/jats:italic>. 60%, and non\u2010responders have a dismal prognosis. Novel therapies for aggressive lymphomas, including those failing <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>, are needed. We performed a phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study of paclitaxel, topotecan and rituximab (<jats:styled-content style=\"fixed-case\">TTR<\/jats:styled-content>) in patients with relapsed or refractory diffuse large <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010cell, follicular grade <jats:styled-content style=\"fixed-case\">IIIB<\/jats:styled-content>, or transformed lymphomas, including those who previously failed <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>. The median age of the 72 patients enrolled was 54\u00a0years. Responding patients were offered <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> after two courses. The overall response rate was 69% for all patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a049\/71) and 45% for those who previously failed <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a09\/20). With a median follow up of 125\u00a0months for the censored observations, the overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) and progression\u2010free survival at 5\u00a0years was 39% and 27%, respectively. Responding patients who received <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> had an <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> of 63% at 5\u00a0years. Our results demonstrate that <jats:styled-content style=\"fixed-case\">TTR<\/jats:styled-content> is an effective salvage regimen for patients with relapsed aggressive <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010cell lymphomas, including those who previously failed <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content>. Given the declining therapeutic outcomes of salvage <jats:styled-content style=\"fixed-case\">PBC<\/jats:styled-content> in the rituximab era, further evaluation of <jats:styled-content style=\"fixed-case\">TTR<\/jats:styled-content> is warranted.<\/jats:p>","DOI":"10.1111\/bjh.13014","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T07:13:06Z","timestamp":1404803586000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive <scp>B<\/scp>\u2010cell non\u2010<scp>H<\/scp>odgkin lymphoma"],"prefix":"10.1111","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Thomas Jefferson University Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Florida Gainesville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Loyer","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging The University of Texas M. D. Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Lymphoma Service Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/8.suppl_1.S119"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05603.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.030"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.498"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701665970"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600814490"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"issue":"10","key":"e_1_2_8_13_1","first-page":"820a","article-title":"Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma","volume":"86","author":"Preti H.A.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453308X343527"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood.V118.21.1628.1628","article-title":"Vinorelbine, paclitaxel, etoposide, cisplatin and cytarabine (VTEPA) is an effective salvage therapy for relapsed\/refractory (R\/R) Hodgkin lymphoma (HL) but not for R\/R diffuse large B cell lymphoma (DLBCL)","volume":"118","author":"Sinha R.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.05.007"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood.V122.21.764.764","article-title":"Diffuse large B\u2010cell lymphoma (DLBCL) patients failing second\u2010line R\u2010DHAP or R\u2010ICE chemotherapy included in the coral study","volume":"122","author":"Van Den Neste E.","year":"2013","journal-title":"Blood"},{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","author":"Swerdlow S.H.","key":"e_1_2_8_18_1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.643406"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2012.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011172215216"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13014","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:49:17Z","timestamp":1696265357000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/bjh.13014"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13014","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2014,7,8]]},"assertion":[{"value":"2014-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}